

Madhav V Dhodapkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5842366/publications.pdf>

Version: 2024-02-01

83
papers

4,697
citations

126907

33
h-index

102487

66
g-index

83
all docs

83
docs citations

83
times ranked

8713
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. <i>Leukemia</i> , 2022, 36, 591-595.	7.2	6
2	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	1.6	31
3	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	1.6	26
4	Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8064-8064.	1.6	2
5	Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8062-8062.	1.6	0
6	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	1.6	19
7	The impact of complex karyotype identified by conventional cytogenetics on survival outcomes of 1,000 patients with newly diagnosed myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8063-8063.	1.6	1
8	Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8054-8054.	1.6	2
9	Analysis of long-term outcomes in R-ISS stage 2 multiple myeloma with and without the presence of high-risk cytogenetics.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8059-8059.	1.6	0
10	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021, 96, E68-E71.	4.1	7
11	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021, 137, 3604-3615.	1.4	44
12	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	5.0	15
13	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. <i>Blood Cancer Discovery</i> , 2021, 2, 9-12.	5.0	20
14	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 1541-1554.	7.0	79
15	Tissue-resident memory-like T cells in tumor immunity: Clinical implications. <i>Seminars in Immunology</i> , 2020, 49, 101415.	5.6	15
16	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
17	Smoldering Myeloma and the Art of War. <i>Journal of Clinical Oncology</i> , 2020, 38, 2363-2365.	1.6	10
18	Reply to N. Biran et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1368-1369.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 286-291.	1.1	28
20	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	1.6	148
21	Game of Bones: How Myeloma Manipulates Its Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 625199.	2.8	24
22	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. <i>JCI Insight</i> , 2020, 5, .	5.0	43
23	Risk-associated alterations in marrow T cells in pediatric leukemia. <i>JCI Insight</i> , 2020, 5, .	5.0	23
24	Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8507-8507.	1.6	22
25	SOHO State of the Art Updates and Next Questions: T-Cellâ€“Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptorâ€“Modified T Cells and Bispecific T-Cellâ€“Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 537-544.	0.4	18
26	Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?. <i>Frontiers in Immunology</i> , 2019, 10, 2385.	4.8	6
27	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019, 125, 2364-2382.	4.1	100
28	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019, 9, 94.	6.2	104
29	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019, 125, 416-423.	4.1	36
30	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8001-8001.	1.6	17
31	MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. <i>Blood</i> , 2018, 131, 2500-2501.	1.4	16
32	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	5.0	140
33	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. <i>Frontiers in Immunology</i> , 2018, 9, 2204.	4.8	45
34	Elotuzumab monotherapy in patients with smoldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018, 182, 495-503.	2.5	30
35	Antigen-mediated regulation in monoclonal gammopathies and myeloma. <i>JCI Insight</i> , 2018, 3, .	5.0	43
36	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018, 132, 3241-3241.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Evomelaâ,ç in Myeloma Autotransplants. Blood, 2018, 132, 3446-3446.	1.4	2
38	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2018, 132, 3294-3294.	1.4	2
39	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	1.4	0
40	Type II NKT Cells and Their Emerging Role in Health and Disease. Journal of Immunology, 2017, 198, 1015-1021.	0.8	102
41	Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 296-304.e2.	0.4	39
42	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.9	116
43	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
44	Natural Killer T Cells in Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1178.	4.8	186
45	Hematologic Malignancies: Plasma Cell Disorders. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 561-568.	3.8	11
46	A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, TPS8053-TPS8053.	1.6	3
47	Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7944-7945.	7.1	8
48	MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood, 2016, 128, 2599-2606.	1.4	133
49	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
50	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nature Medicine, 2016, 22, 1351-1357.	30.7	132
51	Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. New England Journal of Medicine, 2016, 374, 555-561.	27.0	167
52	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology, 2016, 5, e1071008.	4.6	545
53	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight, 2016, 1, e88955.	5.0	111
54	ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. Journal of Clinical Investigation, 2016, 126, 3905-3916.	8.2	81

#	ARTICLE	IF	CITATIONS
55	Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. <i>Blood</i> , 2016, 128, 2139-2139.	1.4	1
56	Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. <i>Blood</i> , 2015, 125, 1256-1271.	1.4	119
57	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). <i>Haematologica</i> , 2015, 100, 1214-1221.	3.5	44
58	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	4.6	119
59	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. <i>Blood</i> , 2015, 125, 4042-4051.	1.4	103
60	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.8	362
61	Conditional overexpression of TGF β 2 promotes pulmonary inflammation, apoptosis and mortality via TGF β 2R2 in the developing mouse lung. <i>Respiratory Research</i> , 2015, 16, 4.	3.6	54
62	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. <i>Blood</i> , 2015, 126, 120-120.	1.4	1
63	Fluzone [®] High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. <i>Blood</i> , 2015, 126, 3058-3058.	1.4	1
64	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	1.8	395
65	Nanoparticle-Mediated Combinatorial Targeting of Multiple Human Dendritic Cell (DC) Subsets Leads to Enhanced T Cell Activation via IL-15-Dependent DC Crosstalk. <i>Journal of Immunology</i> , 2014, 193, 2297-2305.	0.8	39
66	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolmmunology</i> , 2014, 3, e963424.	4.6	62
67	Targeting human dendritic cells in situ to improve vaccines. <i>Immunology Letters</i> , 2014, 162, 59-67.	2.5	88
68	Dual Face of Immune Microenvironment in Myeloma. <i>Blood</i> , 2014, 124, SCI-50-SCI-50.	1.4	0
69	Personalized Immune-Interception of Cancer and the Battle of Two Adaptive Systems—When Is the Time Right?. <i>Cancer Prevention Research</i> , 2013, 6, 173-176.	1.5	6
70	Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group. <i>Blood</i> , 2013, 122, 3174-3174.	1.4	2
71	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Blood</i> , 2012, 120, 4079-4079.	1.4	1
72	Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.. <i>Blood</i> , 2012, 120, 2933-2933.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study. <i>Blood</i> , 2012, 120, 4944-4944.	1.4	0
74	Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols â€ Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS). <i>Blood</i> , 2012, 120, 198-198.	1.4	0
75	Vaccines Targeting Cancer Stem Cells. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 397-402.	2.0	15
76	Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges. <i>Clinical Immunology</i> , 2011, 140, 160-166.	3.2	51
77	Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 413-418.	4.2	11
78	Immunity to stemness genes in human cancer. <i>Current Opinion in Immunology</i> , 2010, 22, 245-250.	5.5	30
79	Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Groupâ€directed intergroup trial S9003. <i>Blood</i> , 2009, 113, 793-796.	1.4	60
80	Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 796.	3.0	29
81	Role of chaperones and FcÎ³R in immunogenic death. <i>Current Opinion in Immunology</i> , 2008, 20, 512-517.	5.5	13
82	Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. <i>Blood</i> , 2008, 112, 1308-1316.	1.4	136
83	Selective blockade of the inhibitory FcÎ³ receptor (FcÎ³RIIB) in human dendritic cells and monocytes induces a type I interferon response program. <i>Journal of Experimental Medicine</i> , 2007, 204, 1359-1369.	8.5	132